• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Blitzer Michael

    7/21/25 4:15:22 PM ET
    $BACQ
    Get the next $BACQ alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    BLITZER MICHAEL

    (Last) (First) (Middle)
    1345 AVENUE OF THE AMERICAS,
    FL 47

    (Street)
    NEW YORK NY 10105

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    07/10/2025
    3. Issuer Name and Ticker or Trading Symbol
    Bleichroeder Acquisition Corp. I [ BACQ ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Michael Blitzer 07/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BACQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BACQ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BACQ
    SEC Filings

    View All

    SEC Form 425 filed by Inflection Point Acquisition Corp. IV

    425 - INFLECTION POINT ACQUISITION CORP. IV (0002028707) (Subject)

    11/19/25 9:11:38 AM ET
    $BACQ

    SEC Form 425 filed by Inflection Point Acquisition Corp. IV

    425 - INFLECTION POINT ACQUISITION CORP. IV (0002028707) (Subject)

    11/18/25 4:30:01 PM ET
    $BACQ

    SEC Form 425 filed by Inflection Point Acquisition Corp. IV

    425 - INFLECTION POINT ACQUISITION CORP. IV (0002028707) (Subject)

    11/17/25 9:24:21 AM ET
    $BACQ

    $BACQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Folino Robert

    3 - Bleichroeder Acquisition Corp. I (0002028707) (Issuer)

    7/21/25 4:15:19 PM ET
    $BACQ

    SEC Form 3 filed by new insider Shannon Kevin George

    3 - Bleichroeder Acquisition Corp. I (0002028707) (Issuer)

    7/21/25 4:15:21 PM ET
    $BACQ

    SEC Form 3 filed by new insider Blitzer Michael

    3 - Bleichroeder Acquisition Corp. I (0002028707) (Issuer)

    7/21/25 4:15:22 PM ET
    $BACQ

    $BACQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merlin Expands Executive Team Ahead of Public Listing

    Leslie Ravestein joins as Chief Legal Officer, David Lasater as Chief People Officer, and Pablo Gonzalez as Senior Vice President of Engineering Merlin Labs, Inc. ("Merlin"), a leading developer of assured, autonomous flight technology for defense customers, today announced key additions to its executive leadership team to optimize the organization in advance of its public listing via a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). The hires include two C-Suite additions, Leslie Ravestein as Chief Legal Officer and David Lasater as Chief People Officer, to strengthen corporate governance, drive operational excellence, and elevate talent strategy. Merlin al

    11/19/25 9:00:00 AM ET
    $AKAM
    $BACQ
    $DELL
    Real Estate
    Computer Manufacturing
    Technology
    Computer Software: Prepackaged Software

    Merlin Labs, Inc. and Inflection Point Acquisition Corp. IV Announce Upsizing of PIPE Investment to More Than $200 Million

    Inflection Point and investors increase PIPE commitments to more than $200 million, including over $85 million of pre-funded PIPE capital Merlin Labs, Inc. ("Merlin"), a leading developer of assured, autonomous flight technology for defense customers, and Inflection Point Acquisition Corp. IV (NASDAQ:BACQ) ("Inflection Point") today announced a significant increase to their previously disclosed private investment in public equity ("PIPE"). The increase comes from both new investors and existing investors increasing their commitments, bringing total PIPE commitments to more than $200 million, of which over $85 million has already been funded. This represents a substantial increase from t

    11/17/25 9:00:00 AM ET
    $BACQ

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy road

    11/4/25 9:00:00 AM ET
    $ASTR
    $BACQ
    $DNA
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BACQ
    Leadership Updates

    Live Leadership Updates

    View All

    Merlin Expands Executive Team Ahead of Public Listing

    Leslie Ravestein joins as Chief Legal Officer, David Lasater as Chief People Officer, and Pablo Gonzalez as Senior Vice President of Engineering Merlin Labs, Inc. ("Merlin"), a leading developer of assured, autonomous flight technology for defense customers, today announced key additions to its executive leadership team to optimize the organization in advance of its public listing via a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). The hires include two C-Suite additions, Leslie Ravestein as Chief Legal Officer and David Lasater as Chief People Officer, to strengthen corporate governance, drive operational excellence, and elevate talent strategy. Merlin al

    11/19/25 9:00:00 AM ET
    $AKAM
    $BACQ
    $DELL
    Real Estate
    Computer Manufacturing
    Technology
    Computer Software: Prepackaged Software

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy road

    11/4/25 9:00:00 AM ET
    $ASTR
    $BACQ
    $DNA
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care